Gunderson Dettmer advised Remix Therapeutics on the deal.Remix Therapeutics, a Massachusetts-based biotech company, announced its $70 million Series B financing which included participation from Surveyor, Foresite Capital,…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
